Profitelligence Profitelligence · Filing Ledger Open ILMN research →

Form 8-K · Current Report · Filed 2026-04-02

Illumina Nominates David P. King to Board of Directors

Illumina, Inc. announced on April 2, 2026, that Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board of Directors effective May 21, 2026. The Board has nominated David P. King for election as a director at the 2026 annual meeting of stockholders. Dr. King brings extensive experience in healthcare and life sciences, having served as Executive Chairman and CEO of Laboratory Corporation of America Holdings and currently holding director positions at several healthcare companies. The retirements are not due to any dispute with the company or the Board.

Filer
Illumina, Inc. ILMN · NASDAQ
Filed
Accession
0001110803-26-000082
CIK
0001110803
Signal
Medium impactHealthcare

Items reported

Item events

Reported Item

Board Member Departure Board Member Appointed

Market reaction

Close before filing

$126.63

Next session

+0.9%

Since filing

+62.0%

Latest close

$205.10

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from ILMN reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, ILMN insiders reported 20 Form 4 transactions — net selling of $62.3M.

Full ILMN insider history →

About Illumina, Inc.

Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Never miss another ILMN filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts